MannKind | MNKD - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
Adma Biologics USD 193.58M 124.25M 2026-03
BioCryst Pharmaceuticals USD 395.2M 33.48M 2026-03
Eli Lilly USD 39.37B 1.5B 2026-03
Halozyme Therapeutics USD 1.94B 206.73M 2026-03
Insmed USD 542.22M 1.25M 2026-03
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
MacroGenics USD 68.71M 1.29M 2026-03
MannKind USD 548.07M 371K 2026-03
Merck USD 46.67B 77M 2026-03
Minerva Neurosciences USD 0 86.58M 2024-09
Novavax USD 246.3M 200K 2025-12
Novo Nordisk DKK 14.02B 224.49M 2025-09
Pfizer USD 60.57B 1.08B 2026-03
Sanofi EUR 13.84B 1.88B 2026-03
Xencor USD 82.12M 5.64M 2026-03